Kotaro Yamashita Selected Research

Kotaro Yamashita Research Topics

Disease

36	Esophageal Neoplasms (Esophageal Cancer) 09/2022 - 08/2015
14	Esophageal Squamous Cell Carcinoma 09/2022 - 01/2016
13	Neoplasms (Cancer) 07/2022 - 08/2015
9	Stomach Neoplasms (Stomach Cancer) 07/2022 - 09/2017
5	Pneumonia (Pneumonitis) 06/2022 - 01/2018
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 07/2022 - 01/2022
2	Wounds and Injuries (Trauma) 10/2022 - 04/2022
2	Anastomotic Leak 06/2022 - 01/2017
2	Body Weight (Weight, Body) 06/2022 - 09/2017
2	Hemorrhage 04/2022 - 04/2022
2	Infections 04/2022 - 01/2016
2	Squamous Cell Neoplasms (Squamous Cell Cancer) 11/2021 - 10/2021
2	Inflammation (Inflammations) 10/2021 - 01/2021
1	Starvation 06/2022
1	Pancreatic Fistula (Pancreatic Fistulas) 06/2022
1	Weight Loss (Weight Reduction) 06/2022
1	Lymphatic Metastasis 04/2022
1	Adenocarcinoma 01/2022
1	Diarrhea 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Febrile Neutropenia 01/2022
1	Lung Neoplasms (Lung Cancer) 11/2021
1	Sarcopenia 11/2021
1	Margins of Excision 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Residual Neoplasm 01/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021
1	Aspiration Pneumonia 09/2020
1	Paralysis (Palsy) 12/2019
1	Abdominal Obesity 11/2018
1	Vascular Ring 05/2018
1	Delirium 01/2018
1	Pain (Aches) 01/2018

Drug/Important Bio-Agent (IBA)

3	Indicators and Reagents (Reagents)IBA 06/2022 - 11/2021
3	GhrelinIBA 06/2022 - 01/2021
3	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 08/2015
3	Docetaxel (Taxotere)FDA Link 01/2022 - 10/2021
2	Hemostatics (Antihemorrhagics)IBA 10/2022 - 04/2022
2	Proteins (Proteins, Gene)FDA Link 04/2022 - 12/2017
2	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 10/2021
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 11/2019
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 12/2020
2	Pharmaceutical PreparationsIBA 11/2021 - 01/2021
2	AntibodiesIBA 07/2021 - 01/2017
1	NivolumabIBA 07/2022
1	Immune Checkpoint InhibitorsIBA 07/2022
1	regorafenibIBA 07/2022
1	Biomarkers (Surrogate Marker)IBA 07/2022
1	Programmed Cell Death 1 ReceptorIBA 07/2022
1	Growth Hormone (Somatotropin)IBA 06/2022
1	Hormones (Hormone)IBA 06/2022
1	squamous cell carcinoma-related antigenIBA 04/2022
1	Heparin (Liquaemin)FDA LinkGeneric 04/2022
1	AntigensIBA 04/2022
1	Imatinib Mesylate (Gleevec)FDA Link 01/2022
1	Acetic Acid (Vinegar)FDA LinkGeneric 01/2022
1	AcidsIBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 11/2021
1	eprenetapoptIBA 11/2021
1	Gefitinib (Iressa)FDA Link 11/2021
1	imidazoleacetic acid (IMAC)IBA 11/2021
1	C-Reactive ProteinIBA 10/2021
1	Amylases FDA Link 10/2021
1	Propranolol (Inderal)FDA LinkGeneric 01/2021
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2021
1	LipopolysaccharidesIBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2021
1	E-SelectinIBA 01/2021
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2021
1	Circulating Tumor DNAIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Polymethyl Methacrylate (Sol)IBA 11/2019
1	Leucovorin (Folinic Acid)FDA Link 11/2019
1	Autophagy-Related ProteinsIBA 12/2017
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2017
1	MicroRNAs (MicroRNA)IBA 08/2015

Therapy/Procedure

30	Esophagectomy 09/2022 - 01/2017
13	Neoadjuvant Therapy 04/2022 - 01/2017
12	Drug Therapy (Chemotherapy) 01/2022 - 08/2015
9	Gastrectomy 07/2022 - 09/2017
4	Therapeutics 07/2022 - 01/2017
2	Chemoradiotherapy 09/2022 - 05/2018
2	Adjuvant Chemotherapy 05/2022 - 01/2021
2	Enteral Nutrition (Feeding, Tube) 01/2022 - 01/2021
2	Radiotherapy 01/2021 - 09/2020
1	Aftercare (After-Treatment) 07/2022
1	Intravenous Infusions 06/2022
1	Endoscopes 04/2022
1	Surgical Instruments (Clip) 04/2022
1	Combination Drug Therapy (Combination Chemotherapy) 01/2022
1	Parenteral Nutrition 01/2021
1	Tracheostomy 05/2020
1	Oral Hygiene (Dental Hygiene) 01/2018
1	Perioperative Care 01/2018
1	Nutritional Support (Artificial Feeding) 01/2018
1	Operative Time 01/2018
1	Combined Modality Therapy 01/2017